Miglustat

• Description :

  Miglustat (N-Butyldeoxynojirimycin) is an orally active and reversible ceramide glucosyltransferase inhibitor. Miglustat can be used for the research of type I gaucher disease[1].

• Product Name Alternative :

  N-Butyldeoxynojirimycin; NB-DNJ; OGT 918

• UNSPSC :

  12352005

• Hazard Statement :

  H315, H319, H335

• Target :

  Glucosylceramide Synthase (GCS)

• Type :

  Reference compound

• Related Pathways :

  Neuronal Signaling

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Inflammation/Immunology; Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/miglustat.html

• Purity :

  99.86

• Solubility :

  H2O : 250 mg/mL (ultrasonic)

• Smiles :

  O[C@H]1[C@H](O)[C@@H](CO)N(CCCC)C[C@@H]1O

• Molecular Formula :

  C10H21NO4

• Molecular Weight :

  219.28

• Precautions :

  H315, H319, H335

• References & Citations :

  [1]Maria Cristina Dechecchi, et al. Anti-inflammatory effect of miglustat in bronchial epithelial cells. J Cyst Fibros. 2008 Nov;7 (6) :555-65. |[2]G D'Arcangelo, et al. Miglustat Reverts the Impairment of Synaptic Plasticity in a Mouse Model of NPC Disease. Neural Plast. 2016:2016:3830424.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, stored under nitrogen)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Citation 01 :

  Cell Rep. 2022 Jul 5;40 (1) :111049.|Front Pharmacol. 2023 Jun 26:14:1191692. |J Virol. 2025 Mar 18;99 (3) :e0001825.|Nat Commun. 2024 Aug 14;15 (1) :6970.|Preprints. 2023 Dec 20.|Cell. 2019 Dec 12;179 (7) :1483-1498.e22.

• CAS Number :

  [72599-27-0]